Page 119 - MemoriaESP-Eng

www.ciberesp.es

These series are useful to identify prognostic markers, prediction of therapeutic

response and toxicity of chemotherapy and radiotherapy.

• IDENTIFICATION OF NEW THERAPEUTIC TARGETS.

We use of bioinformatics tools for the identification of genes involved in cancer.

This is a complex task since it requires in vivo and in vitro validation of hypothe-
ses generated by bioinformatics models using genomic and proteomic data.

• cArMonA FJ, AzuArA D, berenguer-llergo A, FernánDez AF, bionDo s, De ocA J. DNA
Most relevant
methylation biomarkers for noninvasive diagnosis of colorectal cancer.Cancer Prev
scientific Res (Phila). 2013 Jul;6(7):656-65.

articles
• AzuArA D, roDríguez-MorAntA F, De ocA J, sAnJuAn x, guArDiolA J, lobAton t. Novel

methylation panel for the early detection of neoplasia in high-risk ulcerative colitis ó
and Crohn’s colitis patients.Inflamm Bowel Dis. 2013 Jan;19(1):165-73.

• l-D A, F l, M M, l-D s, M-D FD, D V á
pezorigAeliubADAlóenénDezópezorigAorónurAnelAlle
J. ICO Amplicon NGS Data Analysis: A Web Tool for Variant Detection in Common
High-Risk Hereditary Cancer Genes Analyzed by Amplicon GS Junior Next-Generation

Sequencing.Hum Mutat. 2013 Nov 14;.

• FernnDez-rozADillA c, cAzier Jb, Moreno V, crous-bou M, guinó e, Durán g. Phar-

macogenomics in colorectal cancer: a genome-wide association study to predict
toxicity after 5-fluorouracil or FOLFOX administration.Pharmacogenomics J. 2013

Jun;13(3):209-17.

• tiAn s, siMon i, Moreno V, roepMAn p, tAbernero J, snel M. A combined oncogenic
pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer

classification and cetuximab treatment prediction.Gut. 2013 Apr;62(4):540-9.

The group focuses its research on a main own project: COLONOMICS and four
Highlights
collaborative projects: MCC-Spain, CORECT, EPICOLON and INMENSE. The main
project, COLONOMICS: Integration of molecular basis of colorectal cancer for the

detection and validation of new biomarkers (www.colonomics.org) has allowed

us identifying a plasma protein -COL10A1- as a candidate biomarker for early
diagnosis of colorectal cancer. We have renewed the Spanish Patent and prepared

the manuscript for publishing the results. In the project MCC-Spain we lead the

working group on drugs also have worked intensively in family predisposition to
cancer genetic susceptibility. The CORECT project is a collaboration with groups

from the U.S., mainly from the University of South California (USC) and Fred
Hutchinson Cancer Research Center (FHCRC). We have responsibility to analyze

gene-environment interactions in GWAS studies of colorectal cancer. In collabo-

ration with the group EPICOLON (CIBERHed and CIBERRer) have validated se-
veral genetic polymorphisms that confer susceptibility to colorectal cancer and 13
20
prediction of chemotherapy toxicity. In colaboration with the INMENSE group we T
OR
have identified several genetic polymorphisms that increase the risk of multiple P
myeloma. We have published two papers on statistical methods to analyze genetic RE
L
epidemiology studies in collaboration with Prof. Graffelman (UPC) and a protocol A
for the analysis of mutations using next-generation sequencing data in the BRCA1 NU
N
and BRCA2 genes. In the line of biomarkers to predict therapeutic response we A
P /
have published molecular profiles of colorectal tumors with different mutations S
that determine sensitivity to treatment with cetuximab. In the line of colorec- RE
E
tal cancer screening assessment and improvement, we evaluated the quality of IB
C
screening colonoscopy and published several papers on therapeutic strategies in
inflammatory bowel disease.
119